XBI icon

SPDR S&P Biotech ETF

755 hedge funds and large institutions have $9.15B invested in SPDR S&P Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 252 increasing their positions, 253 reducing their positions, and 97 closing their positions.

Holders
755
Holders Change
-19
Holders Change %
-2.45%
% of All Funds
10.98%
Holding in Top 10
18
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-21.74%
% of All Funds
0.26%
New
88
Increased
252
Reduced
253
Closed
97
Calls
$1.59B
Puts
$2.95B
Net Calls
-$1.36B
Net Calls Change
+$358M
Name Market Value Shares Shares
Change
Shares
Change %
BA
851
Ballast Advisors
Minnesota
-74 Closed
AFG
852
Albion Financial Group
Utah
-70 Closed
CWA
853
Core Wealth Advisors
Florida
-26 Closed
PVH
854
Psagot Value Holdings
Israel
-20 Closed
ACM
855
AIGH Capital Management
Maryland
SCM
856
Soleus Capital Management
Connecticut
Nomura Holdings
857
Nomura Holdings
Japan
SI
858
Sofinnova Investments
California
RA
859
Rosalind Advisors
Ontario, Canada
IC
860
Ikarian Capital
Texas
PI
861
PEAK6 Investments
Illinois
PCM
862
Pentwater Capital Management
Florida
EIM
863
Elliott Investment Management
Florida
SAM
864
Simplify Asset Management
Nevada
GTC
865
Ghost Tree Capital
New York
UOC
866
UBS O'Connor
Illinois
FCM
867
Farallon Capital Management
California
LPC
868
Lion Point Capital
New York
SFM
869
Sphera Funds Management
Israel
WAM
870
Weiss Asset Management
Massachusetts
AG
871
Artal Group
Luxembourg
SC
872
Stempoint Capital
New York
PHS
873
PFM Health Sciences
California
LCM
874
Laurion Capital Management
New York
ACM
875
Atika Capital Management
New York